Pharmacogenomics Market Growth, Report, Trends, Forecast 2027

Summary

Report Description

The global pharmacogenomics market is expected to grow at a robust rate during the forecast period. This can be ascribed to the growing popularity and adoption of personalized medicine in the field of healthcare. Pharmacogenomics studies the way a patient’s DNA affects the way his/her body responds to drugs. The growing prevalence of various chronic diseases such as cancer, cardiovascular diseases, respiratory ailments, renal disorders, among others has significantly increased the demand for developing personalized treatment for the treatment of these diseases, thereby driving the growth of global pharmacogenomics market. Additionally, increasing research & development activities along with various companies entering the personalized medicine space is expected to create lucrative opportunities for the growth of global pharmacogenomics market. For instance, in June 2020, Infosys Limited launched personalized medicine solution for the pharmaceutical industry to digitally transform their processes and drive stronger business outcomes.

Increasing Rate of Adverse Drug Reaction

Adverse Drug Reactions (ADRs) include medication-related side effects that develop during clinical use. Furthermore, they can continue for a long time, decreasing a patient's quality of life. ADRs can cause morbidity and fatality in severe circumstances. The increasing number of medications on the market, the rapid rise of polypharmacy to treat different disorders especially in the elderly population, among others are all contributing to the global occurrence of ADRs. The fast growth in the number of ADR cases is driving the demand for more effective treatment regimens. Precision medicine and pharmacogenomics offer a feasible answer to this problem by identifying patients who require specific therapeutic modules that will give good therapy while reducing/eliminating the possibility of any ADR. With established attempts to address such important problems, the global pharmacogenomics market growth is expected to witness significant growth in the coming years.

Increasing Research & Development Activities

The growing research & development activities for developing treatments and drugs taking into consideration the genetic makeup and effect of environment and surroundings on the human health is expected to create lucrative opportunities for the market growth through 2027. Precision medicine or personalized medicine forms the basis of pharmacogenomics, the growing adoption and demand for personalized medicine is further expected to support the growth of global pharmacogenomics. Additionally, biotechnology & pharmaceutical companies and academic & research institutions worldwide are making investments, increasing their research & development funds and related activities, conducting clinical trials, among others related to pharmacogenomics, thereby creating opportunities for the market growth in the coming years. For instance, according to a report published by National Institute of Health of the United States in May 2022, the expenditure on research & development activities related to cancer genomics increased from USD861 million in 2016 to USD1,220 million in 2022. Similarly, the research and development activities related to personalized medicines is increasing across other parts of the globe also. For instance, in October 2021, the Israel Precision Medicine Partnership (IPMP) awarded funding of about USD 9.9 million to 11 projects in Israel for the research of personalized medicine that includes cancers, Crohn’s disease, and rare diseases.

Download Free Sample Report

Market Segmentation

The global pharmacogenomics market can be segmented by technology, by service, by application, by end user, by region. Based on technology, the market can be categorized into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. Based on by service, the market can be fragmented into genotyping, SNP identification, pharmacogenetic testing, and others. Based on application, the market can be grouped into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others. Based on end user, the market can be classified into hospitals & clinics, biotechnology & pharmaceutical companies, and others. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States dominated the pharmacogenomics market among all the countries globally on account of increasing research and development activities in the country. In 2022, the revenue in scientific research & development is projected to reach USD8.11 billion in the United States.

Market Players

Abbott Laboratories, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., AstraZeneca Plc., F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Eurofins Scientific SE, Pacific Biosciences of California Inc., Qiagen N.V., PerkinElmer, Inc., Oxford Nanopore Technologies Limited, Agilent Technologies, Inc., Myriad Genetics, Inc, Admera Health, LLC are some of the leading players operating in the global pharmacogenomics market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	· By Technology · By Service · By Application · By End User · By Region
Regional scope	North America; Asia Pacific; Europe; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE; Egypt; Turkey
Key companies profiled	Abbott Laboratories, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., AstraZeneca Plc., F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Eurofins Scientific SE, Pacific Biosciences of California Inc., Qiagen N.V., PerkinElmer, Inc., Oxford Nanopore Technologies Limited, Agilent Technologies, Inc., Myriad Genetics, Inc, Admera Health, LLC
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global pharmacogenomics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Market, By Technology:

PCR
Sequencing
Microarray
Gel Electrophoresis
Mass Spectrometry
Others

Pharmacogenomics Market, By Service:

Genotyping
SNP Identification
Pharmacogenetic Testing
Others

· Pharmacogenomics Market, By Application:

o Drug Discovery

o Oncology

o Neurology and Psychiatry

o Pain Management

o Cardiovascular Diseases

o Others

· Pharmacogenomics Market, By End User:

o Hospitals & Clinics

o Biotechnology & Pharmaceutical Companies

o Others

· Pharmacogenomics Market, By Region:

North America

United States
Canada
Mexico

Europe

Germany
France
United Kingdom
Spain
Italy

Asia Pacific

China
India
Japan
South Korea
Australia

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Egypt

§ Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global pharmacogenomics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Pharmacogenomics market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Pharmacogenomics Market

5. Voice of Customer

6. Global Pharmacogenomics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, Others)

6.2.2. By Service (Genotyping, SNP Identification, Pharmacogenetic Testing, Others)

6.2.3. By Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, Others)

6.2.4. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Others)

6.2.5. By Company (2021)

6.2.6. By Region

6.3. Market Map

7. North America Pharmacogenomics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Technology

7.2.2. By Service

7.2.3. By Application

7.2.4. By End User

7.2.5. By Country

7.3. North America: Country Analysis

7.3.1. United States Pharmacogenomics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Technology

7.3.1.2.2. By Service

7.3.1.2.3. By Application

7.3.1.2.4. By End User

7.3.2. Canada Pharmacogenomics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Technology

7.3.2.2.2. By Service

7.3.2.2.3. By Application

7.3.2.2.4. By End User

7.3.3. Mexico Pharmacogenomics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Technology

7.3.3.2.2. By Service

7.3.3.2.3. By Application

7.3.3.2.4. By End User

8. Europe Pharmacogenomics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Technology

8.2.2. By Service

8.2.3. By Application

8.2.4. By End User

8.2.5. By Country

8.3. Europe: Country Analysis

8.3.1. France Pharmacogenomics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Technology

8.3.1.2.2. By Service

8.3.1.2.3. By Application

8.3.1.2.4. By End User

8.3.2. Germany Pharmacogenomics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Technology

8.3.2.2.2. By Service

8.3.2.2.3. By Application

8.3.2.2.4. By End User

8.3.3. United Kingdom Pharmacogenomics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Technology

8.3.3.2.2. By Service

8.3.3.2.3. By Application

8.3.3.2.4. By End User

8.3.4. Italy Pharmacogenomics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Technology

8.3.4.2.2. By Service

8.3.4.2.3. By Application

8.3.4.2.4. By End User

8.3.5. Spain Pharmacogenomics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Technology

8.3.5.2.2. By Service

8.3.5.2.3. By Application

8.3.5.2.4. By End User

9. Asia Pacific Pharmacogenomics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Technology

9.2.2. By Service

9.2.3. By Application

9.2.4. By End User

9.2.5. By Country

9.3. Asia Pacific: Country Analysis

9.3.1. China Pharmacogenomics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Technology

9.3.1.2.2. By Service

9.3.1.2.3. By Application

9.3.1.2.4. By End User

9.3.2. India Pharmacogenomics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Technology

9.3.2.2.2. By Service

9.3.2.2.3. By Application

9.3.2.2.4. By End User

9.3.3. Japan Pharmacogenomics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Technology

9.3.3.2.2. By Service

9.3.3.2.3. By Application

9.3.3.2.4. By End User

9.3.4. South Korea Pharmacogenomics Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Technology

9.3.4.2.2. By Service

9.3.4.2.3. By Application

9.3.4.2.4. By End User

9.3.5. Australia Pharmacogenomics Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Technology

9.3.5.2.2. By Service

9.3.5.2.3. By Application

9.3.5.2.4. By End User

10. South America Pharmacogenomics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Technology

10.2.2. By Service

10.2.3. By Application

10.2.4. By End User

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Pharmacogenomics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Technology

10.3.1.2.2. By Service

10.3.1.2.3. By Application

10.3.1.2.4. By End User

10.3.2. Argentina Pharmacogenomics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Technology

10.3.2.2.2. By Service

10.3.2.2.3. By Application

10.3.2.2.4. By End User

10.3.3. Colombia Pharmacogenomics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Technology

10.3.3.2.2. By Service

10.3.3.2.3. By Application

10.3.3.2.4. By End User

11. Middle East and Africa Pharmacogenomics Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Technology

11.2.2. By Service

11.2.3. By Application

11.2.4. By End User

11.2.5. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Pharmacogenomics Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Technology

11.3.1.2.2. By Service

11.3.1.2.3. By Application

11.3.1.2.4. By End User

11.3.2. Saudi Arabia Pharmacogenomics Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Technology

11.3.2.2.2. By Service

11.3.2.2.3. By Application

11.3.2.2.4. By End User

11.3.3. UAE Pharmacogenomics Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Technology

11.3.3.2.2. By Service

11.3.3.2.3. By Application

11.3.3.2.4. By End User

11.3.4. Egypt Pharmacogenomics Market Outlook

11.3.4.1. Market Size & Forecast

11.3.4.1.1. By Value

11.3.4.2. Market Share & Forecast

11.3.4.2.1. By Technology

11.3.4.2.2. By Service

11.3.4.2.3. By Application

11.3.4.2.4. By End User

11.3.5. Turkey Pharmacogenomics Market Outlook

11.3.5.1. Market Size & Forecast

11.3.5.1.1. By Value

11.3.5.2. Market Share & Forecast

11.3.5.2.1. By Technology

11.3.5.2.2. By Service

11.3.5.2.3. By Application

11.3.5.2.4. By End User

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. Abbott Laboratories, Inc.

14.2. Illumina, Inc.

14.3. Thermo Fischer Scientific, Inc.

14.4. AstraZeneca Plc.

14.5. F.Hoffmann-La Roche AG

14.6. Bio-Rad Laboratories, Inc.

14.7. Becton, Dickinson and Company

14.8. Eurofins Scientific SE

14.9. Pacific Biosciences of California Inc.

14.10. Qiagen N.V.

14.11. PerkinElmer, Inc.

14.12. Oxford Nanopore Technologies Limited

14.13. Agilent Technologies, Inc.

14.14. Myriad Genetics, Inc

14.15. Admera Health, LLC

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Pharmacogenomics Market?

Increase in the geriatric population, increased awareness of patients towards personalized therapy, among others are some of the factors driving the growth of global pharmacogenomics market.

Who are the top players operating in the Pharmacogenomics Market?

Abbott Laboratories, Inc., Illumina, Inc., Thermo Fischer Scientific, Inc., AstraZeneca Plc., F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Eurofins Scientific SE, Pacific Biosciences of California Inc., Qiagen N.V., PerkinElmer, Inc., Oxford Nanopore Technologies Limited, Agilent Technologies, Inc., Myriad Genetics, Inc, Admera Health, LLC, among others are some of the leading players operating in the global pharmacogenomics market.